Elan has licensed its NanoCrystal technology to pharmaceutical firm EntreMed.
Under the terms of the licensing agreement, Elan will receive royalties if EntreMed's NanoCrystal-based products are successfully launched on the market. Additionally, Elan will receive royalty payments based on sales of Panzem NCD.
Elan's NanoCrystal Technology is a drug delivery technology that is effective in poorly water-soluble compounds. An increasing number of drugs are poorly water-soluble, leading to their rejection by the body.
NanoCrystal technology is part of a suite of technologies that Elan's business offers to third-party clients.
READ MORE
Elan Drug Technologies has 30 products in 40 countries.